ARCHIVES

Drug Development: ODAC Discussion May Offer Clues For Sponsors of Cytostatic Drugs

This article is from The Cancer Letter archive.

Vol. 25 No. 24 | June 16, 1999

Download PDF Visit The Full Archive

Related Articles

Amgen’s Kepivance Approved For Severe Oral Mucositis

January 28, 2005

Combined analysis moves Herceptin to adjuvant setting in breast cancer.

May 27, 2005

Congressional News: Senate Subcommittee Recommends $2.3 Bil. Budget for NCI

September 13, 1996

In Brief: Greenwald Reorganizing DCPC, Elevates Surveillance to Program, Moves Branches

February 3, 1989

FDA Approves Ixempra For Metastatic Breast Cancer Resistant To Other Therapy

October 26, 2007

NCI Awards $10 Million To States for Cervix Screening

September 27, 1974